BGIG - ETF AI Analysis
Top Page
Bahl & Gaynor Income Growth ETF (BGIG)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Overall Performance
The ETF has delivered strong year-to-date and recent short-term performance, showing solid momentum.
Leading Growth and Income Holdings
Several of the largest positions, including major health care, financial, and semiconductor companies, have shown strong gains, helping drive the fund’s returns.
Broad Sector Diversification
The fund is spread across many sectors such as technology, health care, financials, energy, and utilities, which helps reduce the impact of weakness in any single industry.
Negative Factors
High U.S. Market Concentration
Almost all of the ETF’s assets are invested in U.S. companies, offering very limited geographic diversification.
Meaningful Single-Stock Exposure
The top holdings each make up a noticeable share of the portfolio, which increases the impact if any of these companies run into trouble.
Mixed Performance Among Top Tech and Financial Names
A few large technology and financial holdings have shown weaker or negative performance recently, which can drag on the fund’s results if the trend continues.
BGIG vs. SPDR S&P 500 ETF (SPY)
AUM2.24B
RegionNorth America
Expense Ratio0.45%
Beta0.60
IssuerBahl & Gaynor
Inception DateSep 14, 2023
Dividend Yield1.68%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume128,210
30 Day Avg. Volume109,564
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.22Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering49
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BGIG Summary
The Bahl & Gaynor Income Growth ETF (BGIG) is an actively managed fund that focuses on large U.S. companies that pay dividends and have room to grow over time. It doesn’t track a specific index, but instead builds a broad mix across sectors like technology, health care, and financials. Well-known holdings include Microsoft and Johnson & Johnson. Someone might invest in BGIG to seek a mix of regular income from dividends and long-term growth from strong, established businesses. A key risk is that it is heavily invested in U.S. large-cap stocks, so its value can rise and fall with the overall stock market.
How much will it cost me?The Bahl & Gaynor Income Growth ETF (BGIG) has an expense ratio of 0.45%, meaning you’ll pay $4.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, which typically involves more research and decision-making compared to passively managed funds. However, this cost reflects the expertise in selecting a curated portfolio of large-cap companies focused on income and growth.
What would affect this ETF?The BGIG ETF, with its focus on large-cap U.S. companies and sectors like technology, healthcare, and financials, could benefit from continued innovation in tech and stable demand for healthcare products. However, rising interest rates or economic slowdowns might negatively impact financial and consumer sectors, while regulatory changes in healthcare or technology could pose risks. Its emphasis on dividend-paying companies provides stability but may underperform during high-growth market cycles.
BGIG Top 10 Holdings
BGIG leans heavily on U.S. blue chips, with a clear tilt toward tech and health care to power both income and growth. Microsoft and TSMC are doing much of the heavy lifting, with AI and chip demand keeping them in the driver’s seat, while Broadcom’s more mixed stretch has it contributing but not shining. On the defensive side, steady names like Johnson & Johnson and AbbVie are quietly supporting returns, and UnitedHealth has been a bit choppy but still helpful over the longer run. Overall, the fund is U.S.-centric with a tech-and-health-care heartbeat.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Microsoft | 4.96% | $110.83M | $3.75T | 1.35% | 79 Outperform | |
| Broadcom | 4.66% | $104.08M | $1.77T | 24.01% | 76 Outperform | |
| TSMC | 4.55% | $101.68M | $1.98T | 79.33% | 81 Outperform | |
| UnitedHealth | 4.48% | $100.02M | $354.59B | 26.81% | 72 Outperform | |
| Johnson & Johnson | 4.10% | $91.57M | $640.48B | 51.48% | 78 Outperform | |
| AbbVie | 4.03% | $90.13M | $456.18B | 21.42% | 66 Neutral | |
| PNC Financial | 3.96% | $88.43M | $97.15B | 16.77% | 71 Outperform | |
| Apollo Global Management | 3.50% | $78.16M | $78.80B | -0.87% | 75 Outperform | |
| Eli Lilly & Co | 3.23% | $72.09M | $1.11T | 60.54% | 72 Outperform | |
| Williams Co | 3.17% | $70.79M | $90.75B | 27.38% | 76 Outperform |
BGIG Technical Analysis
Neutral
―
Price Trends
36.36
Positive
35.51
Positive
34.14
Positive
Market Momentum
0.12
Positive
47.73
Neutral
9.66
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BGIG, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 37.07, equal to the 50-day MA of 36.36, and equal to the 200-day MA of 34.14, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 9.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BGIG.
BGIG Peer Comparison
Comparison Results
Performance Comparison
BGIG
Bahl & Gaynor Income Growth ETF
36.70
5.95
19.35%
FELC
Fidelity Enhanced Large Cap Core ETF
―
―
―
TCAF
T. Rowe Price Capital Appreciation Equity ETF
―
―
―
DIVO
Amplify CWP Enhanced Dividend Income ETF
―
―
―
GPIX
Goldman Sachs S&P 500 Core Premium Income ETF
―
―
―
GPIQ
Goldman Sachs Nasdaq 100 Core Premium Income ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents